- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Cannabis Weekly Round-Up: Canopy's Fiscal Year Net Loss Reaches C$320 Million
As cannabis companies across the board share their financial results, a leading Canadian producer reported another difficult period.
Shares of Canopy Growth (NASDAQ:CGC,TSX:WEED) struggled out of the gate at the end of the week as the company reported another difficult period with heavy losses.
Also this past week, a Canadian producer announced the launch of a new lifestyle CBD brand in the UK.
Keep reading to find out more cannabis highlights from the past five days.
Canopy reports losses in fiscal quarter and year
Despite highlighting improvements over previous financial periods, Canopy Growth once again posted a net loss in its quarterly results. The cannabis firm reported a figure of C$579 million for its Q4 2022 fiscal period.
The company celebrated the retention of a leading position in the flower category for adult-use cannabis in Canada. However, it reported a 5 percent decline in net revenue to C$520 million for its full fiscal year period.
Looking ahead, the company told shareholders it plans to continue making strategic investments across the board, and will toe the line of how much business it can pursue in the US.
Canopy said it expects to reach positive adjusted EBITDA by fiscal 2024.
“In the fiscal year ahead, we will remain focused on growing our market share in the key segments that will drive profitable growth and continuing to scale our premium brands across North America," CEO David Klein said.
Shares of the cannabis producer saw a double-digit loss in value to open the trading day on Friday (May 27). As of 11:47 a.m. EST, the company was down nearly 15 percent for a share price of US$4.72 in New York.
Canopy had a volatile trading week as it climbed to a weekly high of US$5.50 on Thursday (May 26). Over a year-to-date period, the company is down nearly 50 percent in value.
Tilray pursues lifestyle category in UK
Tilray Brands (NASDAQ:TLRY,TSX:TLRY) confirmed the launch of POLLEN, a new CBD lifestyle brand designed for UK consumers. The line of products has three different gummy packs each with 300 milligrams of CBD.
According to Tilray, these products are vegan-friendly. Initially they will only be available on Amazon UK, but the firm hinted that it plans to make them more widely available to consumers through local retailers.
Cannabis company news
- The Valens Company (NASDAQ:VLNS,TSX:VLNS)has increased its market share in the recreational category for cannabis in Canada. “In short, we are on track to hit our 2022 objectives to become a top five player in vapes, edibles and beverages and a top ten player in flower products by year end," Tyler Robson, CEO of the company, said.
- Aurora Cannabis (NASDAQ:ACB,TSX:ACB)confirmed an uptick to a bought-deal financing led by Canaccord Genuity and BMO Capital Markets. The new deal will bring US$150 million by way of the company offering 61.2 million shares.
- Ayr Wellness (CSE:AYR.A,OTCQX:AYRWF)shared its financial results for first quarter. “It has been well-telegraphed by our peers that Q1 was a challenging period for the industry,” CEO Jonathan Sandelman said. “However, we have maintained or even increased retail market share across most of our footprint despite this challenging backdrop, while also increasing wholesale revenue.”
Don't forget to follow us @INN_Cannabis for real-time updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
- Cannabis Companies: Stocks on the TSXV | INN ›
- CSE Marijuana Stocks | INN ›
- Top 5 Cannabis Stocks in 2022 ›
- US Cannabis Stocks | INN ›
- Invest in Cannabis: TSX Cannabis Stocks | INN ›
The Beginner’s Guide to Investing in Biotech
Ready to invest in biotech? Our beginner's guide makes it simple to get started.
Download your investing guide today.
Learn About Exciting Investing Opportunities in the Biotech Sector
Your Newsletter Preferences
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
Bryan is a Senior Editor with INN. After graduating from the Langara journalism program he did some freelance reporting with community newspapers in British Columbia. He initially wrote about the life science space for INN and now spends his time covering the marijuana market, from Canadian LPs to US-based companies, and the impact of this sector on investors.
Learn about our editorial policies.